Marina G. Cavuoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marina G. Cavuoto has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Matthew Paul Pase
School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia
8 shared publications - Stephanie R. Yiallourou
School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia
8 shared publications - Alexa S. Beiser
Boston University School of Public Health
4 shared publications - Andrée-Ann Baril
Center for Advanced Research in Sleep Medicine (CARSM), Research Center of the CIUSSS-NIM, Hôpital du Sacré-Coeur de Montréal
4 shared publications - Ella Rowsthorn
Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Australia
4 shared publications - Jayandra Jung Himali
Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center San Antonio
4 shared publications
Latest Publications
- 25 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (4) , e218182
Association of Sleep Variables With Cognitive Performance and the Risk of Dementia in the Sleep and Dementia Consortium
Background and ObjectivesSleep is multidimensional, and it remains unclear which aspects are most relevant to cognition and dementia risk. We aimed to apply a data-driven approach to identify clust...
- 25 August 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (4) , e218182
Association of Sleep Variables With Cognitive Performance and the Risk of Dementia in the Sleep and Dementia Consortium
Background and ObjectivesSleep is multidimensional, and it remains unclear which aspects are most relevant to cognition and dementia risk. We aimed to apply a data-driven approach to identify clust...
- 26 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (10) , e214935
Association of 24-Hour Blood Pressure Variability With Cognition and Brain MRI Markers of Structural Change in Adults in Mid- to Late-Life
Background and ObjectivesBlood pressure (BP) fluctuates across the 24-hour period. High 24-hour BP variability (BPV) is associated with cardiovascular disease risk, yet its relevance for brain heal...
- 26 May 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (10) , e214935
Association of 24-Hour Blood Pressure Variability With Cognition and Brain MRI Markers of Structural Change in Adults in Mid- to Late-Life
Background and ObjectivesBlood pressure (BP) fluctuates across the 24-hour period. High 24-hour BP variability (BPV) is associated with cardiovascular disease risk, yet its relevance for brain heal...
- 14 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (7) , e214773
Association of an Aquaporin-4 Haplotype With Cognition, Brain Volume, and Dementia Risk in Community-Dwelling Individuals Without Dementia
Background and ObjectivesThe aquaporin-4 (AQP4) water channel plays an integral role in clearing brain waste. However, little is known about whether variations in the AQP4 gene contributes to brain...
- 14 April 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 106 (7) , e214773
Association of an Aquaporin-4 Haplotype With Cognition, Brain Volume, and Dementia Risk in Community-Dwelling Individuals Without Dementia
Background and ObjectivesThe aquaporin-4 (AQP4) water channel plays an integral role in clearing brain waste. However, little is known about whether variations in the AQP4 gene contributes to brain...
- Open Access
- 24 July 2025
- Published by Springer Nature in Journal of Population Research
- Vol. 42 (3) , 1-26
Estimating and projecting the population living with dementia at the local area scale in Australia
As Australia’s population ages, the number of people living with dementia will grow considerably. Understanding local changes in the number of people living with dementia will facilitate suitable planning, costing, and service delivery for health and aged care services. To inform this task, this study presents estimates and projections from 2021 to 2036 of Australians living with dementia at the state and territory level, and at the finer regional SA3 level. Estimates and projections were prepared for 3 scenarios: where dementia prevalence rates by age, sex, and SA3 area (1) remain fixed (Constant Prevalence), (2) decrease exponentially by 1% per year (Decreasing Prevalence), or (3) increase exponentially by 1% per year (Increasing Prevalence). Regardless of the dementia prevalence scenario, there is projected to be strong growth of the number of people living with dementia between 2021 and 36 due to large growth in the older population. Even in the best-case, Decreasing Prevalence scenario, the number of persons living with dementia is projected to increase from 388,441 in 2021 to approximately 554,000 by 2036—a 42.8% rise. This increase is regionally heterogeneous, albeit correlated with numerical ageing. In all scenarios, by 2036, many SA3 areas will have fewer than 20 working-age persons for each person living with dementia, presenting challenges for the provision of dementia care. These results highlight the need for urgent local level policy and planning decisions to support dementia prevention, diagnosis, and prepare healthcare systems to support the care and quality of life of persons living with dementia.
- 24 July 2025
- Published by Springer Nature in Journal of Population Research
- Vol. 42 (3) , 1-26
Open AccessEstimating and projecting the population living with dementia at the local area scale in Australia
As Australia’s population ages, the number of people living with dementia will grow considerably. Understanding local changes in the number of people living with dementia will facilitate suitable planning, costing, and service delivery for health and aged care services. To inform this task, this study presents estimates and projections from 2021 to 2036 of Australians living with dementia at the state and territory level, and at the finer regional SA3 level. Estimates and projections were prepared for 3 scenarios: where dementia prevalence rates by age, sex, and SA3 area (1) remain fixed (Constant Prevalence), (2) decrease exponentially by 1% per year (Decreasing Prevalence), or (3) increase exponentially by 1% per year (Increasing Prevalence). Regardless of the dementia prevalence scenario, there is projected to be strong growth of the number of people living with dementia between 2021 and 36 due to large growth in the older population. Even in the best-case, Decreasing Prevalence scenario, the number of persons living with dementia is projected to increase from 388,441 in 2021 to approximately 554,000 by 2036—a 42.8% rise. This increase is regionally heterogeneous, albeit correlated with numerical ageing. In all scenarios, by 2036, many SA3 areas will have fewer than 20 working-age persons for each person living with dementia, presenting challenges for the provision of dementia care. These results highlight the need for urgent local level policy and planning decisions to support dementia prevention, diagnosis, and prepare healthcare systems to support the care and quality of life of persons living with dementia.
- Open Access
Factor Analysis of Multimodal MRI, Biofluid and Vascular Health Biomarkers Reveals Latent Constructs of Brain Health
Individual imaging and fluid biomarkers provide insights into specific components of brain health, but integrated multimodal approaches are necessary to capture the complex, interrelated biological systems that contribute to brain homeostasis and neurodegenerative disease. Using data from the Brain and Cognitive Health (BACH) cohort study (N=127; mean age=67 years, 68% women), we performed an exploratory factor analysis to identify latent constructs of brain health. We included multimodal neurovascular imaging markers, brain atrophy metrics, plasma Alzheimer’s disease (AD) biomarkers and cardiovascular risk factors. Five constructs emerged: “Brain & Vascular Health” (greater hippocampal volume, basal ganglia enlarged perivascular spaces [ePVS], cerebral blood flow and HDL cholesterol; lower ventricle volume and BMI); “Structural Integrity” (greater cortical thickness, fractional anisotropy and basal ganglia ePVS); “Fluid Transport” (greater white matter ePVS and Free Water); “AD Biomarkers” (higher phosphorylated tau [pTau]181 and pTau217; lower amyloid-beta 42/40 ratio); and “Neuronal Injury” (higher glial fibrillary acidic protein and neurofilament light chain). All constructs were associated with age (β=-0.70–0.39, p ≤.014), except for Fluid Transport ( p >.05). Brain & Vascular Health and Structural Integrity ( partial r =.305, p <.001), and AD Biomarkers and Neuronal Injury ( partial r =.248, p =.005) were positively correlated. Only Brain & Vascular Health was associated with global cognition (β=0.27, SE=0.13, p =.043). These findings provide a data-driven framework for examining distinct constructs underlying vascular health, fluid regulation and neurodegenerative pathology. We demonstrate the utility of using multiple biomarkers to probe these biological systems, paving the way for future research to explore how these systems change across diverse neurodegenerative conditions.
Open AccessFactor Analysis of Multimodal MRI, Biofluid and Vascular Health Biomarkers Reveals Latent Constructs of Brain Health
Individual imaging and fluid biomarkers provide insights into specific components of brain health, but integrated multimodal approaches are necessary to capture the complex, interrelated biological systems that contribute to brain homeostasis and neurodegenerative disease. Using data from the Brain and Cognitive Health (BACH) cohort study (N=127; mean age=67 years, 68% women), we performed an exploratory factor analysis to identify latent constructs of brain health. We included multimodal neurovascular imaging markers, brain atrophy metrics, plasma Alzheimer’s disease (AD) biomarkers and cardiovascular risk factors. Five constructs emerged: “Brain & Vascular Health” (greater hippocampal volume, basal ganglia enlarged perivascular spaces [ePVS], cerebral blood flow and HDL cholesterol; lower ventricle volume and BMI); “Structural Integrity” (greater cortical thickness, fractional anisotropy and basal ganglia ePVS); “Fluid Transport” (greater white matter ePVS and Free Water); “AD Biomarkers” (higher phosphorylated tau [pTau]181 and pTau217; lower amyloid-beta 42/40 ratio); and “Neuronal Injury” (higher glial fibrillary acidic protein and neurofilament light chain). All constructs were associated with age (β=-0.70–0.39, p ≤.014), except for Fluid Transport ( p >.05). Brain & Vascular Health and Structural Integrity ( partial r =.305, p <.001), and AD Biomarkers and Neuronal Injury ( partial r =.248, p =.005) were positively correlated. Only Brain & Vascular Health was associated with global cognition (β=0.27, SE=0.13, p =.043). These findings provide a data-driven framework for examining distinct constructs underlying vascular health, fluid regulation and neurodegenerative pathology. We demonstrate the utility of using multiple biomarkers to probe these biological systems, paving the way for future research to explore how these systems change across diverse neurodegenerative conditions.
- Open Access
Plasma pTau-217 Correlates with Brain Atrophy, Cognition, and CSF Biomarkers in a Cognitively Healthy Community Cohort
Plasma biomarkers are promising for detecting Alzheimer’s disease (AD) pathology, but their role in cognitively healthy individuals remains unclear. Plasma pTau-217 has high diagnostic accuracy for clinical and prodromal AD, yet its relevance in preclinical stages is underexplored. We examined if plasma biomarkers of AD, neurodegeneration, and neuroinflammation were associated with cognition, brain structure, and their cerebrospinal fluid (CSF) counterparts in dementia-free older adults. We studied community-based, dementia-free older adults from the Brain and Cognitive Health (BACH) cohort. Neuropsychological testing assessed global cognition (MMSE), memory (Logical Memory II), visual processing (Hooper Visual Organization Test), processing speed (Trail Making Test-A), and reasoning (Similarities). Paired plasma and CSF biomarkers (pTau-217, pTau-181, GFAP, NfL, Aβ42/40) were measured using SIMOA. MRI-derived cortical thickness was used as a neurodegeneration marker. Multivariable linear regression assessed associations between log 10 -transformed plasma biomarker levels, cognition (adjusted for age, sex, education, hypertension, hyperlipidemia, diabetes), and cortical thickness (adjusted for age, sex, education, and intracranial volume). Pearson’s correlations and Bland-Altman plots evaluated plasma-CSF agreement. There were 147 dementia-free participants (mean age±SD: 66.7±7.7 years; 56 % women). Higher plasma pTau-217 levels associated with lower global cognition scores (β -0.80, 95% C.I. -1.56, -0.03, p=0.041) and abstract reasoning (β -0.86, 95% confidence interval [C.I.] -1.62, -0.09, p=0.028). Greater plasma pTau-217 also associated with lower global cortical thickness (βeta [β] -0.21, 95% confidence interval [C.I]. -0.37, -0.06, per log unit change; p=0.006). No associations were found between the plasma biomarkers and processing speed or visual processing (p>0.05 for all). Among 47 participants with paired plasma-CSF biomarkers, plasma pTau-217 showed the strongest correlation with its CSF counterpart (R=0.76, p<0.0001), outperforming pTau-181 (R=0.61, p<0.0001), GFAP (R=0.66, p<0.0001), NfL (R=0.56, p<0.0001), and Aβ42/40 (R=0.53, p=0.0001). In conclusion, plasma pTau-217 levels were associated with both cognition and cortical thickness in dementia-free older adults. All plasma biomarkers correlated significantly with their CSF counterpart. These findings reinforce the utility of plasma biomarkers, particularly pTau-217, as indicators of neurodegenerative processes, even in asymptomatic individuals.
Open AccessPlasma pTau-217 Correlates with Brain Atrophy, Cognition, and CSF Biomarkers in a Cognitively Healthy Community Cohort
Plasma biomarkers are promising for detecting Alzheimer’s disease (AD) pathology, but their role in cognitively healthy individuals remains unclear. Plasma pTau-217 has high diagnostic accuracy for clinical and prodromal AD, yet its relevance in preclinical stages is underexplored. We examined if plasma biomarkers of AD, neurodegeneration, and neuroinflammation were associated with cognition, brain structure, and their cerebrospinal fluid (CSF) counterparts in dementia-free older adults. We studied community-based, dementia-free older adults from the Brain and Cognitive Health (BACH) cohort. Neuropsychological testing assessed global cognition (MMSE), memory (Logical Memory II), visual processing (Hooper Visual Organization Test), processing speed (Trail Making Test-A), and reasoning (Similarities). Paired plasma and CSF biomarkers (pTau-217, pTau-181, GFAP, NfL, Aβ42/40) were measured using SIMOA. MRI-derived cortical thickness was used as a neurodegeneration marker. Multivariable linear regression assessed associations between log 10 -transformed plasma biomarker levels, cognition (adjusted for age, sex, education, hypertension, hyperlipidemia, diabetes), and cortical thickness (adjusted for age, sex, education, and intracranial volume). Pearson’s correlations and Bland-Altman plots evaluated plasma-CSF agreement. There were 147 dementia-free participants (mean age±SD: 66.7±7.7 years; 56 % women). Higher plasma pTau-217 levels associated with lower global cognition scores (β -0.80, 95% C.I. -1.56, -0.03, p=0.041) and abstract reasoning (β -0.86, 95% confidence interval [C.I.] -1.62, -0.09, p=0.028). Greater plasma pTau-217 also associated with lower global cortical thickness (βeta [β] -0.21, 95% confidence interval [C.I]. -0.37, -0.06, per log unit change; p=0.006). No associations were found between the plasma biomarkers and processing speed or visual processing (p>0.05 for all). Among 47 participants with paired plasma-CSF biomarkers, plasma pTau-217 showed the strongest correlation with its CSF counterpart (R=0.76, p<0.0001), outperforming pTau-181 (R=0.61, p<0.0001), GFAP (R=0.66, p<0.0001), NfL (R=0.56, p<0.0001), and Aβ42/40 (R=0.53, p=0.0001). In conclusion, plasma pTau-217 levels were associated with both cognition and cortical thickness in dementia-free older adults. All plasma biomarkers correlated significantly with their CSF counterpart. These findings reinforce the utility of plasma biomarkers, particularly pTau-217, as indicators of neurodegenerative processes, even in asymptomatic individuals.
- Open Access
- 25 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035132
Short Sleep Duration and Hypertension: A Double Hit for the Brain
Background: Short sleep duration has been associated with an increased risk of cognitive impairment and dementia. Short sleep is associated with elevated blood pressure, yet the combined insult of short sleep and hypertension on brain health remains unclear. We assessed whether the association of sleep duration with cognition and vascular brain injury was moderated by hypertensive status. Methods and Results: A total of 682 dementia‐free participants (mean age, 62±9 years; 53% women) from the Framingham Heart Study completed assessments of cognition, office blood pressure, and self‐reported habitual and polysomnography‐derived sleep duration; 637 underwent brain magnetic resonance imaging. Linear regressions were performed to assess effect modification by hypertensive status on total sleep time (coded in hours) and cognitive and magnetic resonance imaging outcomes. There was a significant interaction between sleep duration and hypertensive status when predicting executive function/processing speed (Trail Making B‐A) and white matter hyperintensities. When results were stratified by hypertensive status, longer sleep duration was associated with better executive functioning/processing speed scores in the hypertensive group (meaning that shorter sleep duration was associated with poorer executive function/processing speed scores) (self‐report sleep: β=0.041 [95% CI, 0.012–0.069], P =0.005; polysomnography sleep: β=0.045 [95% CI, 0.002–0.087], P =0.038), but no association was observed for the normotensive group. Similarly, shorter subjective sleep duration was associated with higher white matter hyperintensity burden in the hypertensive group (β=−0.115 [95% CI, −0.227 to −0.004], P =0.042), but not in the normotensive group. Conclusions: In individuals with hypertension, shorter sleep duration was associated with worse cognitive performance and greater brain injury.
- 25 October 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (21) , e035132
Open AccessShort Sleep Duration and Hypertension: A Double Hit for the Brain
Background: Short sleep duration has been associated with an increased risk of cognitive impairment and dementia. Short sleep is associated with elevated blood pressure, yet the combined insult of short sleep and hypertension on brain health remains unclear. We assessed whether the association of sleep duration with cognition and vascular brain injury was moderated by hypertensive status. Methods and Results: A total of 682 dementia‐free participants (mean age, 62±9 years; 53% women) from the Framingham Heart Study completed assessments of cognition, office blood pressure, and self‐reported habitual and polysomnography‐derived sleep duration; 637 underwent brain magnetic resonance imaging. Linear regressions were performed to assess effect modification by hypertensive status on total sleep time (coded in hours) and cognitive and magnetic resonance imaging outcomes. There was a significant interaction between sleep duration and hypertensive status when predicting executive function/processing speed (Trail Making B‐A) and white matter hyperintensities. When results were stratified by hypertensive status, longer sleep duration was associated with better executive functioning/processing speed scores in the hypertensive group (meaning that shorter sleep duration was associated with poorer executive function/processing speed scores) (self‐report sleep: β=0.041 [95% CI, 0.012–0.069], P =0.005; polysomnography sleep: β=0.045 [95% CI, 0.002–0.087], P =0.038), but no association was observed for the normotensive group. Similarly, shorter subjective sleep duration was associated with higher white matter hyperintensity burden in the hypertensive group (β=−0.115 [95% CI, −0.227 to −0.004], P =0.042), but not in the normotensive group. Conclusions: In individuals with hypertension, shorter sleep duration was associated with worse cognitive performance and greater brain injury.
- Open Access
- 12 August 2024
- Published by Taylor & Francis in Neuropsychological Rehabilitation
- Vol. 35 (5) , 1034-1058
Exploring the everyday impacts and memory intervention needs of people with transient epileptic amnesia: A qualitative study
People with transient epileptic amnesia (TEA) experience deficits in memory, however, little is known about their everyday experience of this, and no memory intervention studies have been conducted within this group. Using a two-part qualitative method, this study explored the lived experience of people with TEA and possible avenues for memory intervention. Fourteen people with TEA participated in either a focus group (n = 7) or an online survey (n = 7) to answer questions regarding their memory difficulties, impact on their lives, and strategies to mitigate these problems. Perceived barriers and facilitators to participating in a group memory intervention program were discussed. Thematic content analysis identified key themes regarding impacts on the individual and their relationships. Although some positive outcomes regarding family support and personal acceptance were described, most participants described negative impacts on relationships and mood. A range of strategies to mitigate memory problems were reported, although some people did not use any. Participants identified practical and socio-emotional advantages to memory intervention, with perceived barriers around individual applicability, preferences, and ability to engage. While individual preferences need to be considered, a group-based memory intervention may help address cognitive and mental health concerns, particularly for those newly diagnosed with TEA.
- 12 August 2024
- Published by Taylor & Francis in Neuropsychological Rehabilitation
- Vol. 35 (5) , 1034-1058
Open AccessExploring the everyday impacts and memory intervention needs of people with transient epileptic amnesia: A qualitative study
People with transient epileptic amnesia (TEA) experience deficits in memory, however, little is known about their everyday experience of this, and no memory intervention studies have been conducted within this group. Using a two-part qualitative method, this study explored the lived experience of people with TEA and possible avenues for memory intervention. Fourteen people with TEA participated in either a focus group (n = 7) or an online survey (n = 7) to answer questions regarding their memory difficulties, impact on their lives, and strategies to mitigate these problems. Perceived barriers and facilitators to participating in a group memory intervention program were discussed. Thematic content analysis identified key themes regarding impacts on the individual and their relationships. Although some positive outcomes regarding family support and personal acceptance were described, most participants described negative impacts on relationships and mood. A range of strategies to mitigate memory problems were reported, although some people did not use any. Participants identified practical and socio-emotional advantages to memory intervention, with perceived barriers around individual applicability, preferences, and ability to engage. While individual preferences need to be considered, a group-based memory intervention may help address cognitive and mental health concerns, particularly for those newly diagnosed with TEA.
- Open Access
- 19 March 2024
- Published by Elsevier in Preventive Medicine Reports
- Vol. 41, 102696
Cross-sectional associations between neighborhood characteristics, cognition and dementia risk factor burden in middle-aged and older Australians
- 19 March 2024
- Published by Elsevier in Preventive Medicine Reports
- Vol. 41, 102696
Open AccessCross-sectional associations between neighborhood characteristics, cognition and dementia risk factor burden in middle-aged and older Australians
- 23 January 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (2) , e208029
Association of the Sleep Regularity Index With Incident Dementia and Brain Volume
Irregular sleep may increase the risk of cardiometabolic conditions, but its association with incident dementia is unclear. The aim of this study was to assess the association between sleep regularity, that is, the day-to-day consistency in sleep-wake patterns and the risk of incident dementia and related brain MRI endophenotypes. We used Cox proportional hazard models to investigate the relationships between sleep regularity and incident dementia in 88,094 UK Biobank participants. The sleep regularity index (SRI) was calculated as the probability of being in the same state (asleep/awake) at any 2 time points 24 hours apart, averaged over 7 days of accelerometry. The mean age of the sample was 62 years (SD = 8), 56% were women, and the median SRI was 60 (SD = 10). There were 480 cases of incident dementia over a median 7.2 years of follow-up. Following adjustments for demographic, clinical, and genetic confounders (APOE ε4), there was a nonlinear association between the SRI and dementia hazard (p [global test of spline term] < 0.001) with hazard ratios (HRs) following a U-shape pattern. HRs, relative to the median SRI, were 1.53 (95% CI 1.24-1.89) for participants with SRI at the 5th percentile (SRI = 41) and 1.16 (95% CI 0.89-1.50) for those with SRI at the 95th percentile (SRI = 71). In a subset with brain MRI (n = 15,263), gray matter and hippocampal volume tended to be lowest at the extremes of the SRI. Sleep regularity displayed a U-shaped association with risk of incident dementia. Irregular sleep may represent a novel dementia risk factor.
- 23 January 2024
- Published by Wolters Kluwer Health in Neurology
- Vol. 102 (2) , e208029
Association of the Sleep Regularity Index With Incident Dementia and Brain Volume
Irregular sleep may increase the risk of cardiometabolic conditions, but its association with incident dementia is unclear. The aim of this study was to assess the association between sleep regularity, that is, the day-to-day consistency in sleep-wake patterns and the risk of incident dementia and related brain MRI endophenotypes. We used Cox proportional hazard models to investigate the relationships between sleep regularity and incident dementia in 88,094 UK Biobank participants. The sleep regularity index (SRI) was calculated as the probability of being in the same state (asleep/awake) at any 2 time points 24 hours apart, averaged over 7 days of accelerometry. The mean age of the sample was 62 years (SD = 8), 56% were women, and the median SRI was 60 (SD = 10). There were 480 cases of incident dementia over a median 7.2 years of follow-up. Following adjustments for demographic, clinical, and genetic confounders (APOE ε4), there was a nonlinear association between the SRI and dementia hazard (p [global test of spline term] < 0.001) with hazard ratios (HRs) following a U-shape pattern. HRs, relative to the median SRI, were 1.53 (95% CI 1.24-1.89) for participants with SRI at the 5th percentile (SRI = 41) and 1.16 (95% CI 0.89-1.50) for those with SRI at the 95th percentile (SRI = 71). In a subset with brain MRI (n = 15,263), gray matter and hippocampal volume tended to be lowest at the extremes of the SRI. Sleep regularity displayed a U-shaped association with risk of incident dementia. Irregular sleep may represent a novel dementia risk factor.